Figure 2.

The schematic diagram depicts the extracellular vesicles derived from tumor contain distinct protein cargo which promote tumor progression. Tumor-derived EVs carry a specific protein cargo that aids tumour development. Components in the cargo of TEX (tumor-derived sEVs) cause immune cells to fail in diverse ways, inhibiting the antitumor immune response. TEX initially interacts with immune cells via ligands or antigens that lymphocytes identify through corresponding receptors. TEX binds to the surface membrane before being absorbed into the cytoplasm through receptors.